CSI Market
Sign In | Register

Ayala Pharmaceuticals Inc (ADXS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADXS Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Ayala Pharmaceuticals Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Sep 30 2023) (Jun 30 2023) (Mar 31 2023) (Dec 31 2022)
Operating Activities
Income-48.07
Depreciation & amortization0.37
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Inventory Write-down0.15
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.22
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Embedded Derivative Gain Loss On Embedded Derivative Net-
Warrants Expense-
Value Of Penalty Shares Issued-
Investment Income Interest-
Litigation Settlement Expense-
Employee Stock Purchase Plan Expense-
Debt Conversion Expense-
Lease Incentive Obligation Expense-
Impairment Of Intangible Assets Excluding Goodwill-
Increase Decrease In Contract With Customer Liability-
Amortization Of Deferred Offering Costs-
Remeasurement Of Long Term Warrant Liability-0.14
Gain On Change In Value Of Warrants0.31
Gain On Change In Value Of Preferred Stock Redemption Liability-0.41
Increase Decrease In Operating Lease Rightofuse Assets-
Increase Decrease In Operating Lease Liability-
Increase Decrease In Uncertain Tax Position-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.01
Increase (Decrease) in Accounts Payable, Trade-0.72
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.12
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other-1.49
Other Working Capital-0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities9.89
Discontinued operations0.00
Net Cash flow from Operating Activities-29.49
Investing Activities
Capital Expenditures0.00
Sale of Capital Items4.00
Proceeds from Sale and Maturity of Held-to-maturity Securities0.00
Payments to Acquire Held-to-maturity Securities0.00
Real Estate Investments0.00
Restricted Cash Established With Letter Of Credit Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition1.91
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.04
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities5.95
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings6.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net17.28
Proceeds From Deferred Investment Funds-
Deferred Investment Funds-
Payments Of Treasury Stock Purchased To Pay Employee Withholdings On Equity Awards-
Employee Tax Withholdings Paid On Equity Awards-
Tax Shares Sold To Pay For Employee Tax Withholdings On Equity Awards-
Net Proceeds Of Issuance Of Common Stock And Warrants-
Net Proceeds Of Issuance Of Common Stock-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations2.72
Restricted Cash Current-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Prefunded Warrant Exercises-
Proceeds From Prefunded Warrant Exercises-
Restricted Cash-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities26.00
Effect of exchange rate on cash flow0.03
Discontinued operations0.00
Free Cash Flow-25.49
Total Cash Flow2.49
4 historic quarters locked

Sign in to unlock the full Ayala Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Ayala Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: April 16, 2024
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-24-014822

Figures are derived from filed reports and may be restated. Historical data is subject to revision.